MENLO PARK, Calif.--(BUSINESS WIRE)--Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of U.S. Patent No. 8,129,330 B2 titled “Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof.
MENLO PARK, Calif.--(BUSINESS WIRE)--Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of U.S. Patent No. 8,129,330 B2 titled “Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof.
